NO2686520T3 - - Google Patents
Info
- Publication number
- NO2686520T3 NO2686520T3 NO12759983A NO12759983A NO2686520T3 NO 2686520 T3 NO2686520 T3 NO 2686520T3 NO 12759983 A NO12759983 A NO 12759983A NO 12759983 A NO12759983 A NO 12759983A NO 2686520 T3 NO2686520 T3 NO 2686520T3
- Authority
- NO
- Norway
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/803—Processes of preparation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/80—Complexes comprising metals of Group VIII as the central metal
- B01J2531/82—Metals of the platinum group
- B01J2531/824—Palladium
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Materials Engineering (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Enzymes And Modification Thereof (AREA)
- Curing Cements, Concrete, And Artificial Stone (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161493536P | 2011-06-06 | 2011-06-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO2686520T3 true NO2686520T3 (OSRAM) | 2018-03-17 |
Family
ID=47262177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO12759983A NO2686520T3 (OSRAM) | 2011-06-06 | 2012-03-05 |
Country Status (23)
| Country | Link |
|---|---|
| US (6) | US9145366B2 (OSRAM) |
| EP (5) | EP3683209B1 (OSRAM) |
| JP (6) | JP6290781B2 (OSRAM) |
| KR (5) | KR102000485B1 (OSRAM) |
| CN (1) | CN106518759B (OSRAM) |
| AU (4) | AU2012268426B2 (OSRAM) |
| CA (2) | CA2838194C (OSRAM) |
| CY (4) | CY1117177T1 (OSRAM) |
| DK (4) | DK3000808T3 (OSRAM) |
| ES (4) | ES2771232T3 (OSRAM) |
| HR (4) | HRP20211916T1 (OSRAM) |
| HU (4) | HUE026096T2 (OSRAM) |
| IL (1) | IL229775A (OSRAM) |
| LT (3) | LT3290404T (OSRAM) |
| MX (2) | MX347709B (OSRAM) |
| NO (1) | NO2686520T3 (OSRAM) |
| PL (4) | PL3683209T3 (OSRAM) |
| PT (4) | PT3290404T (OSRAM) |
| RS (3) | RS59902B1 (OSRAM) |
| RU (2) | RU2602083C2 (OSRAM) |
| SI (4) | SI3290404T1 (OSRAM) |
| SM (3) | SMT202000061T1 (OSRAM) |
| WO (1) | WO2012170377A1 (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ601730A (en) | 2006-06-26 | 2014-04-30 | Akebia Therapeutics Inc | Prolyl hydroxylase inhibitors and methods of use |
| NO2686520T3 (OSRAM) * | 2011-06-06 | 2018-03-17 | ||
| PL3007695T3 (pl) * | 2013-06-13 | 2024-07-01 | Akebia Therapeutics, Inc. | Kompozycje i sposoby leczenia niedokrwistości |
| AR099354A1 (es) | 2013-11-15 | 2016-07-20 | Akebia Therapeutics Inc | Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos |
| ES2898476T3 (es) | 2014-09-02 | 2022-03-07 | Sunshine Lake Pharma Co Ltd | Compuesto de quinolona y uso del mismo |
| AU2016209126A1 (en) | 2015-01-23 | 2017-08-10 | Akebia Therapeutics, Inc. | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof |
| US20180065933A1 (en) * | 2015-03-20 | 2018-03-08 | Akebia Therapeutics, Inc. | Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors |
| CN106146395B (zh) * | 2015-03-27 | 2019-01-01 | 沈阳三生制药有限责任公司 | 3-羟基吡啶化合物、其制备方法及其制药用途 |
| UA123308C2 (uk) | 2015-04-01 | 2021-03-17 | Екебіа Терапьютікс, Інк. | Композиції і способи для лікування анемії |
| US10703724B2 (en) | 2016-12-13 | 2020-07-07 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystalline forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino} acetic acid and processes for preparation thereof |
| IL269623B2 (en) * | 2017-03-29 | 2025-05-01 | Emerald Health Pharmaceuticals Inc | Cannabidiol derivatives as inhibitors of the hif prolyl hydroxylases activity |
| WO2019028150A1 (en) | 2017-08-01 | 2019-02-07 | Akebia Therapeutics, Inc. | COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES |
| MX2020011845A (es) * | 2018-05-09 | 2021-01-15 | Akebia Therapeutics Inc | Proceso para preparar acido 2-[[5-(3-clorofenil)-3-hidroxipiridina -2-carbonil]amino]acetico. |
| WO2020075199A1 (en) | 2018-10-12 | 2020-04-16 | Mylan Laboratories Limited | Polymorphic forms of vadadustat |
| EP3887356B1 (en) | 2018-11-28 | 2023-08-02 | Sandoz AG | Multi-component crystals of an orally available hif prolyl hydroxylase inhibitor |
| US12134600B2 (en) | 2019-04-26 | 2024-11-05 | Kaneka Corporation | Method for producing a vadadustat intermediate |
| US11524939B2 (en) | 2019-11-13 | 2022-12-13 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid |
| CN111087343B (zh) * | 2019-11-29 | 2022-02-18 | 万华化学集团股份有限公司 | 一种羟基吡啶配体及其制备方法和催化应用 |
| US20230159462A1 (en) * | 2019-12-10 | 2023-05-25 | Akebia Therapeutics, Inc. | Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative |
| WO2021149724A1 (ja) | 2020-01-24 | 2021-07-29 | Ａｐｓジャパン株式会社 | 光触媒ユニット及び該光触媒ユニットを備えたマスク |
| US20230286918A1 (en) | 2020-07-02 | 2023-09-14 | Akebia Therapeutics, Inc. | Manufacturing process for 3,5-dichloropicolinonitrile for synthesis of vadadustat |
| GB202011431D0 (en) * | 2020-07-23 | 2020-09-09 | Johnson Matthey Plc | Polymorphs of vadadustat and methods for preparing the polymorphs |
| WO2023111990A1 (en) | 2021-12-17 | 2023-06-22 | Akebia Therapeutics, Inc. | Selective phd1 inhibitor compounds, compositions, and methods of use |
| WO2024165507A1 (en) | 2023-02-06 | 2024-08-15 | Institut National de la Santé et de la Recherche Médicale | Use of hif-1α stabilizing agents for the treatment of type i interferonopathies |
Family Cites Families (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3655679A (en) * | 1969-06-25 | 1972-04-11 | Merck & Co Inc | Certain aryl pyridine carboxylic acid derivatives |
| US3703582A (en) * | 1970-04-20 | 1972-11-21 | Merck & Co Inc | Aryl pyridine carboxylic acids in the treatment of inflammation |
| US3894920A (en) | 1971-12-21 | 1975-07-15 | Sagami Chem Res | Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives |
| US4016287A (en) | 1972-07-17 | 1977-04-05 | Boehringer Ingelheim Gmbh | Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof |
| TW219933B (OSRAM) | 1990-02-26 | 1994-02-01 | Lilly Co Eli | |
| US5405613A (en) | 1991-12-11 | 1995-04-11 | Creative Nutrition Canada Corp. | Vitamin/mineral composition |
| TW352384B (en) | 1992-03-24 | 1999-02-11 | Hoechst Ag | Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals |
| DE4219158A1 (de) | 1992-06-11 | 1993-12-16 | Thomae Gmbh Dr K | Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| DK0650960T3 (da) | 1993-11-02 | 1997-09-01 | Hoechst Ag | Substituerede heterocykliske carboxylsyreamid-estere, deres fremstilling og deres anvendelse som lægemidler. |
| ATE149486T1 (de) | 1993-11-02 | 1997-03-15 | Hoechst Ag | Substituierte heterocyclische carbonsäureamide, ihre herstellung und ihre verwendung als arzneimittel |
| TW406076B (en) | 1993-12-30 | 2000-09-21 | Hoechst Ag | Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals |
| DE4410480A1 (de) | 1994-03-25 | 1995-09-28 | Hoechst Ag | Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE4410423A1 (de) | 1994-03-25 | 1995-09-28 | Hoechst Ag | Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US5789426A (en) | 1995-01-20 | 1998-08-04 | Cornell Research Foundation, Inc. | Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation |
| IL135495A (en) | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid |
| JPH09221476A (ja) | 1995-12-15 | 1997-08-26 | Otsuka Pharmaceut Co Ltd | 医薬組成物 |
| JP2000509047A (ja) | 1996-04-30 | 2000-07-18 | ヘキスト・アクチエンゲゼルシヤフト | ３―アルコキシピリジン―２―カルボキサミドエステル類、その製法および薬剤としてのその使用 |
| DE19620041A1 (de) | 1996-05-17 | 1998-01-29 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| DE19650215A1 (de) | 1996-12-04 | 1998-06-10 | Hoechst Ag | 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel |
| US6420427B1 (en) | 1997-10-09 | 2002-07-16 | Ono Pharmaceutical Co., Ltd. | Aminobutyric acid derivatives |
| DE19746287A1 (de) | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| HUP0101482A3 (en) | 1998-03-23 | 2002-12-28 | Aventis Pharm Prod Inc | Piperidinyl and n-amidinopiperidinyl derivatives, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing the same |
| US6159379A (en) | 1999-05-04 | 2000-12-12 | Baker Hughes Incorporated | Organic ammonium salts for the removal of water soluble organics in produced water |
| JP2001048786A (ja) | 1999-08-05 | 2001-02-20 | Yamanouchi Pharmaceut Co Ltd | 三環式ヘテロアリール誘導体 |
| US6589758B1 (en) | 2000-05-19 | 2003-07-08 | Amgen Inc. | Crystal of a kinase-ligand complex and methods of use |
| US6855510B2 (en) | 2001-03-20 | 2005-02-15 | Dana Farber Cancer Institute, Inc. | Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| US6849718B2 (en) | 2001-03-20 | 2005-02-01 | Dana Farber Cancer Institute, Inc. | Muteins of hypoxia inducible factor alpha and methods of use thereof |
| WO2002074981A2 (en) | 2001-03-21 | 2002-09-26 | Isis Innovation Ltd. | Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase |
| SE0101327D0 (sv) | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | New crystalline forms |
| US6566088B1 (en) | 2001-10-04 | 2003-05-20 | Board Of Regents, The University Of Texas System | Prolyl-4-hydroxylases |
| GB0124941D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| EP2324834B1 (en) | 2001-12-06 | 2019-05-08 | Fibrogen, Inc. | Methods of Increasing Endogenous Erythropoietin (EPO) |
| NZ570777A (en) | 2002-05-17 | 2009-04-30 | Celgene Corp | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
| EP1545538A2 (en) * | 2002-08-29 | 2005-06-29 | Merck & Co., Inc. | N-biarylmethyl aminocycloalkanecarboxamide derivatives |
| MXPA05004033A (es) | 2002-10-16 | 2005-06-08 | Isis Innovation | Hidroxilasas de asparaginil y moduladores de las mismas. |
| CA2506799A1 (en) | 2002-11-21 | 2004-06-10 | Eli Lilly And Company | Mixed lineage kinase modulators |
| US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
| US7618940B2 (en) | 2002-12-06 | 2009-11-17 | Fibrogen, Inc. | Fat regulation |
| US7183287B2 (en) | 2003-04-03 | 2007-02-27 | Pharmacia Corporation | Substituted pyrimidinones |
| WO2005007192A2 (en) | 2003-06-06 | 2005-01-27 | Fibrogen, Inc. | Cytoprotection through the use of hif hydroxylase inhibitors |
| US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
| CN103145616B (zh) | 2003-06-06 | 2015-09-30 | 菲布罗根有限公司 | 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途 |
| GB0314129D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| JPWO2005108370A1 (ja) | 2004-04-16 | 2008-03-21 | 味の素株式会社 | ベンゼン化合物 |
| US20080113383A1 (en) | 2004-05-28 | 2008-05-15 | Fibro Gen, Inc. | Hif Prolyl Hydroxylase Activity Assay |
| EP1771418A2 (en) | 2004-05-31 | 2007-04-11 | Tanabe Seiyaku Co., Ltd. | Large conductance calcium-activated k channel opener |
| US8013006B2 (en) | 2004-07-14 | 2011-09-06 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| TW200616969A (en) | 2004-09-17 | 2006-06-01 | Tanabe Seiyaku Co | Imidazole compound |
| US20080213404A1 (en) | 2005-02-04 | 2008-09-04 | Johnson Randall S | Hif Modulating Compounds and Methods of Use Thereof |
| DE102005019712A1 (de) | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
| CN101849943A (zh) | 2005-06-06 | 2010-10-06 | 菲布罗根公司 | 使用HIFα稳定剂的改进的贫血治疗 |
| MX2007016160A (es) | 2005-06-15 | 2008-03-07 | Fibrogen Inc | Uso de moduladoers de hif-1 alfa para el tratamiento contra el cancer. |
| US20070154482A1 (en) | 2005-09-12 | 2007-07-05 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state |
| WO2007038571A2 (en) | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
| US20090176726A1 (en) | 2005-10-11 | 2009-07-09 | Fisher David E | Methods for treating mitf-related disorders |
| CA2634168C (en) | 2005-12-09 | 2013-04-23 | Amgen Inc. | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof |
| EP1971618A2 (en) | 2006-01-09 | 2008-09-24 | Btg International Limited | Modulators of hypoxia inducible factor-1 and related uses |
| EP1983823A1 (en) | 2006-01-17 | 2008-10-29 | VIB vzw | Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration |
| JP4801451B2 (ja) | 2006-01-19 | 2011-10-26 | 株式会社日立ハイテクノロジーズ | 走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法 |
| WO2007084667A2 (en) | 2006-01-19 | 2007-07-26 | Osi Pharmaceutical, Inc. | Fused heterobicyclic kinase inhibitors |
| ITMI20060179A1 (it) | 2006-02-02 | 2007-08-03 | Abiogen Pharma Spa | Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse |
| WO2007101204A1 (en) | 2006-02-27 | 2007-09-07 | Alcon Research, Ltd. | Method of treating glaucoma |
| PE20071020A1 (es) | 2006-03-07 | 2007-12-11 | Smithkline Beecham Corp | Compuestos derivados de glicina n-sustituidos como inhibidores de prolil hidroxilasa |
| US7588924B2 (en) | 2006-03-07 | 2009-09-15 | Procter & Gamble Company | Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase |
| JP2009537558A (ja) | 2006-05-16 | 2009-10-29 | スミスクライン・ビーチャム・コーポレイション | プロリルヒドロキシラーゼ阻害剤 |
| AR061570A1 (es) | 2006-06-23 | 2008-09-03 | Smithkline Beecham Corp | Compuesto de glicina sustituido en el n heteroaromatico composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimientos para preparar dicha composicion farmaceutica y para preparar el compuesto |
| NZ601730A (en) | 2006-06-26 | 2014-04-30 | Akebia Therapeutics Inc | Prolyl hydroxylase inhibitors and methods of use |
| CL2008000065A1 (es) | 2007-01-12 | 2008-09-22 | Smithkline Beecham Corp | Compuestos derivados de glicina n-sustituida, inhibidores de hif prolil hidroxilasas; su proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anemia. |
| CL2008000066A1 (es) | 2007-01-12 | 2008-08-01 | Smithkline Beecham Corp | Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem |
| US20100056563A1 (en) | 2007-04-18 | 2010-03-04 | Deodialsingh Guiadeen | Novel 1.8-naphthyridine compounds |
| CA2683738C (en) | 2007-04-18 | 2012-03-20 | Amgen Inc. | Indanone derivatives that inhibit prolyl hydroxylase |
| CA2685216C (en) | 2007-05-04 | 2014-07-08 | Amgen Inc. | Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity |
| EP2160187B1 (en) | 2007-05-16 | 2013-05-22 | Merck Sharp & Dohme Corp. | Spiroindalones |
| RU2009146851A (ru) | 2007-05-18 | 2011-06-27 | Байер Шеринг Фарма Акциенгезельшафт (DE) | Гетероарил-замещенные пиразольные производные, которые могут использоваться для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом |
| US8268794B2 (en) | 2007-08-06 | 2012-09-18 | Senju Pharmaceutical Co., Ltd. | Pharmaceutical containing HIF-1 alpha and HIF-2 alpha expression inhibitor |
| TW200908984A (en) | 2007-08-07 | 2009-03-01 | Piramal Life Sciences Ltd | Pyridyl derivatives, their preparation and use |
| EP2188295A4 (en) | 2007-08-10 | 2011-11-16 | Crystalgenomics Inc | PYRIDINE DERIVATIVES AND METHODS OF USE |
| WO2009035534A2 (en) | 2007-09-07 | 2009-03-19 | The Cleveland Clinic Foundation | Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif) |
| WO2009039323A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009039321A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009043093A1 (en) | 2007-10-04 | 2009-04-09 | Newsouth Innovations Pty Limited | Hif inhibition |
| WO2009049112A1 (en) | 2007-10-10 | 2009-04-16 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009067790A1 (en) | 2007-11-26 | 2009-06-04 | Uti Limited Partnership | STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION |
| AU2008331480A1 (en) | 2007-11-30 | 2009-06-11 | Glaxosmithkline Llc | Prolyl hydroxylase inhibitors |
| AU2008329746A1 (en) | 2007-11-30 | 2009-06-04 | Glaxosmithkline Llc | Prolyl hydroxylase inhibitors |
| WO2009073669A1 (en) | 2007-12-03 | 2009-06-11 | Fibrogen, Inc. | Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions |
| US20100298324A1 (en) | 2007-12-19 | 2010-11-25 | Smith Kline Beecham Corporation | Prolyl Hydroxylase Inhibitors |
| US20110003013A1 (en) | 2008-01-04 | 2011-01-06 | Garvan Institute Of Medical Research | Method of increasing metabolism |
| EP2252619B1 (en) | 2008-01-11 | 2013-10-09 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity |
| MY150481A (en) * | 2008-03-03 | 2014-01-30 | Irm Llc | Compounds and compositions as tlr activity modulators |
| US20090228298A1 (en) * | 2008-03-04 | 2009-09-10 | The General Electric Company | System and method of morphology feature analysis of physiological data |
| RU2010142937A (ru) * | 2008-03-20 | 2012-04-27 | Форест Лабораториес Холдингс Лимитед (Bm) | НОВЫЕ ПРОИЗВОДНЫЕ ПИПЕРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ СТЕАРОИЛ-КоА ДЕСАТУРАЗЫ |
| AR071997A1 (es) | 2008-06-04 | 2010-07-28 | Bristol Myers Squibb Co | Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina |
| ES2383273T3 (es) * | 2008-07-23 | 2012-06-19 | F. Hoffmann-La Roche Ag | Compuestos heterocíclicos antivíricos |
| CN102149703B (zh) | 2008-09-15 | 2014-09-10 | 卡斯娜莱拉伊诺制药私人有限公司 | 抗癌药物及将其用于治疗转移性恶性黑色素瘤及其他癌症 |
| US8927591B2 (en) | 2008-11-14 | 2015-01-06 | Fibrogen, Inc. | Thiochromene derivatives as HIF hydroxylase inhibitors |
| WO2010113942A1 (ja) * | 2009-03-31 | 2010-10-07 | キッセイ薬品工業株式会社 | インドリジン誘導体及びその医薬用途 |
| NZ600400A (en) | 2009-11-06 | 2014-09-26 | Aerpio Therapeutics Inc | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha |
| NO2686520T3 (OSRAM) * | 2011-06-06 | 2018-03-17 | ||
| CN103717214A (zh) | 2011-06-06 | 2014-04-09 | 阿克比治疗有限公司 | 用于稳定低氧诱导因子-2α作为治疗癌症的方法的化合物和组合物 |
| US20130022974A1 (en) | 2011-06-17 | 2013-01-24 | The Regents Of The University Of Michigan | Dna methylation profiles in cancer |
| CN104024227B8 (zh) | 2011-07-22 | 2025-07-29 | 北京贝美拓新药研发有限公司 | 抑制脯氨酸羟化酶活性的化合物的晶型及其应用 |
| CN105492011A (zh) | 2013-04-08 | 2016-04-13 | 丹尼斯·M·布朗 | 不理想给药化学化合物的治疗增效 |
| PL3007695T3 (pl) | 2013-06-13 | 2024-07-01 | Akebia Therapeutics, Inc. | Kompozycje i sposoby leczenia niedokrwistości |
| AU2014306496A1 (en) | 2013-08-16 | 2016-03-03 | Ohio State Innovation Foundation | Compositions and methods for modulating DNA methylation |
| AR099354A1 (es) | 2013-11-15 | 2016-07-20 | Akebia Therapeutics Inc | Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos |
| CN106132201A (zh) | 2014-01-23 | 2016-11-16 | 阿克比治疗有限公司 | 用于治疗眼部疾病的组合物和方法 |
| AU2016209126A1 (en) | 2015-01-23 | 2017-08-10 | Akebia Therapeutics, Inc. | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof |
| US20180065933A1 (en) | 2015-03-20 | 2018-03-08 | Akebia Therapeutics, Inc. | Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors |
| UA123308C2 (uk) | 2015-04-01 | 2021-03-17 | Екебіа Терапьютікс, Інк. | Композиції і способи для лікування анемії |
| MX2020011845A (es) | 2018-05-09 | 2021-01-15 | Akebia Therapeutics Inc | Proceso para preparar acido 2-[[5-(3-clorofenil)-3-hidroxipiridina -2-carbonil]amino]acetico. |
-
2012
- 2012-03-05 NO NO12759983A patent/NO2686520T3/no unknown
- 2012-06-05 RS RS20200130A patent/RS59902B1/sr unknown
- 2012-06-05 ES ES17191362T patent/ES2771232T3/es active Active
- 2012-06-05 PL PL19214405T patent/PL3683209T3/pl unknown
- 2012-06-05 HR HRP20211916TT patent/HRP20211916T1/hr unknown
- 2012-06-05 AU AU2012268426A patent/AU2012268426B2/en active Active
- 2012-06-05 KR KR1020147000297A patent/KR102000485B1/ko active Active
- 2012-06-05 HR HRP20151416T patent/HRP20151416T1/hr unknown
- 2012-06-05 EP EP19214405.3A patent/EP3683209B1/en active Active
- 2012-06-05 SI SI201231729T patent/SI3290404T1/sl unknown
- 2012-06-05 LT LTEP17191362.7T patent/LT3290404T/lt unknown
- 2012-06-05 HU HUE12796374A patent/HUE026096T2/en unknown
- 2012-06-05 LT LTEP15189822.8T patent/LT3000808T/lt unknown
- 2012-06-05 EP EP15189822.8A patent/EP3000808B1/en active Active
- 2012-06-05 DK DK15189822.8T patent/DK3000808T3/da active
- 2012-06-05 SI SI201231114T patent/SI3000808T1/en unknown
- 2012-06-05 SI SI201231969T patent/SI3683209T1/sl unknown
- 2012-06-05 CA CA2838194A patent/CA2838194C/en active Active
- 2012-06-05 PL PL12796374T patent/PL2718265T3/pl unknown
- 2012-06-05 RU RU2013158640/04A patent/RU2602083C2/ru active
- 2012-06-05 DK DK12796374.2T patent/DK2718265T3/en active
- 2012-06-05 SM SM20200061T patent/SMT202000061T1/it unknown
- 2012-06-05 PT PT171913627T patent/PT3290404T/pt unknown
- 2012-06-05 KR KR1020207029586A patent/KR102293016B1/ko active Active
- 2012-06-05 MX MX2015016579A patent/MX347709B/es unknown
- 2012-06-05 US US13/488,554 patent/US9145366B2/en active Active
- 2012-06-05 ES ES12796374.2T patent/ES2559850T3/es active Active
- 2012-06-05 ES ES19214405T patent/ES2900572T3/es active Active
- 2012-06-05 EP EP12796374.2A patent/EP2718265B1/en active Active
- 2012-06-05 MX MX2013014228A patent/MX337216B/es active IP Right Grant
- 2012-06-05 PT PT192144053T patent/PT3683209T/pt unknown
- 2012-06-05 SI SI201230432T patent/SI2718265T1/sl unknown
- 2012-06-05 PL PL15189822T patent/PL3000808T3/pl unknown
- 2012-06-05 RU RU2016139352A patent/RU2764667C2/ru active
- 2012-06-05 PT PT151898228T patent/PT3000808T/pt unknown
- 2012-06-05 PL PL17191362T patent/PL3290404T3/pl unknown
- 2012-06-05 CN CN201610967348.7A patent/CN106518759B/zh active Active
- 2012-06-05 HU HUE17191362A patent/HUE048044T2/hu unknown
- 2012-06-05 HU HUE19214405A patent/HUE057571T2/hu unknown
- 2012-06-05 LT LTEP19214405.3T patent/LT3683209T/lt unknown
- 2012-06-05 SM SM20170534T patent/SMT201700534T1/it unknown
- 2012-06-05 CA CA3135440A patent/CA3135440A1/en active Pending
- 2012-06-05 HU HUE15189822A patent/HUE034975T2/en unknown
- 2012-06-05 EP EP21206374.7A patent/EP4026829A1/en active Pending
- 2012-06-05 DK DK17191362.7T patent/DK3290404T3/da active
- 2012-06-05 EP EP17191362.7A patent/EP3290404B1/en active Active
- 2012-06-05 PT PT127963742T patent/PT2718265E/pt unknown
- 2012-06-05 KR KR1020197007633A patent/KR102032864B1/ko active Active
- 2012-06-05 JP JP2014514536A patent/JP6290781B2/ja active Active
- 2012-06-05 KR KR1020197007630A patent/KR102059366B1/ko active Active
- 2012-06-05 KR KR1020197037296A patent/KR102171315B1/ko active Active
- 2012-06-05 RS RS20171181A patent/RS56580B1/sr unknown
- 2012-06-05 ES ES15189822.8T patent/ES2647602T3/es active Active
- 2012-06-05 RS RS20160013A patent/RS54517B1/sr unknown
- 2012-06-05 DK DK19214405.3T patent/DK3683209T3/da active
- 2012-06-05 WO PCT/US2012/040833 patent/WO2012170377A1/en not_active Ceased
-
2013
- 2013-12-03 IL IL229775A patent/IL229775A/en active IP Right Grant
-
2015
- 2015-08-24 US US14/833,222 patent/US9776969B2/en active Active
-
2016
- 2016-01-14 CY CY20161100037T patent/CY1117177T1/el unknown
- 2016-01-15 SM SM201600013T patent/SMT201600013B/it unknown
-
2017
- 2017-04-12 AU AU2017202414A patent/AU2017202414B2/en active Active
- 2017-08-31 US US15/692,255 patent/US10246416B2/en active Active
- 2017-11-13 HR HRP20171740TT patent/HRP20171740T1/hr unknown
- 2017-11-15 CY CY20171101202T patent/CY1119605T1/el unknown
-
2018
- 2018-02-08 JP JP2018020595A patent/JP6510094B2/ja active Active
- 2018-10-15 AU AU2018250355A patent/AU2018250355B2/en active Active
-
2019
- 2019-03-13 US US16/352,705 patent/US10738010B2/en active Active
- 2019-04-03 JP JP2019070979A patent/JP6816195B2/ja active Active
-
2020
- 2020-02-03 CY CY20201100087T patent/CY1122639T1/el unknown
- 2020-02-06 HR HRP20200197TT patent/HRP20200197T1/hr unknown
- 2020-07-06 US US16/921,273 patent/US11267785B2/en active Active
- 2020-07-07 AU AU2020204528A patent/AU2020204528B2/en active Active
- 2020-12-23 JP JP2020213442A patent/JP7039682B2/ja active Active
-
2021
- 2021-12-08 CY CY20211101079T patent/CY1124874T1/el unknown
-
2022
- 2022-01-31 US US17/589,118 patent/US20230002323A1/en active Pending
- 2022-03-09 JP JP2022035813A patent/JP7284309B2/ja active Active
-
2023
- 2023-05-18 JP JP2023081959A patent/JP7685552B2/ja active Active